Role of the tumor microenvironment in mediating response to anti-angiogenic therapy.
Despite the development of innovative anti-angiogenic strategies, early clinical trials have not replicated the results observed from preclinical models. One reason for this apparent discrepancy is the fact that tumor endothelium is phenotypically distinct from normal tissue endothelium. Moreover, it has recently become apparent that each individual tumor may display a different angiogenic phenotype. The expression of angiogenic factors in tumors is controlled by both intrinsic factors in the tumor cell and the influence of the host microenvironment. The diversity of angiogenic factor expression in tumors growing at different sites, combined with the fact that endothelial cells in different organs and tumors are phenotypically distinct, constitutes a formidable challenge for the development of effective anti-angiogenic regimens. This review provides an overview of how the microenvironment regulates tumor angiogenesis and affects the efficacy of anti-angiogenic therapy.
Jung
Y D
YD
Department of Cancer Biology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Ahmad
S A
SA
Akagi
Y
Y
Takahashi
Y
Y
Liu
W
W
Reinmuth
N
N
Shaheen
R M
RM
Fan
F
F
Ellis
L M
LM
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D004730:Endothelium, Vascular / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000517:prevention & control*
D020533:Angiogenesis Inhibitors